Physostigmine-induced salivary secretion in the rat.
The purpose of this study was to see if physostigmine, a reversible cholinesterase inhibitor, affects the secretion and composition of saliva of the major salivary glands of the rat. Low doses of physostigmine did not elicit secretion. At higher doses there was significant flow from the parotid and submandibular glands within 5 min; however, no sublingual secretion was observed. The submandibular flow rate was highest for the first 5 min, then declined rapidly. The parotid flow rate initially was one-fifth of the maximum submandibular rate and then gradually decreased. The concentrations of Ca, Na and K of physostigmine-induced parotid saliva, and the Na of submandibular saliva, were similar to those with carbachol stimulation. The Ca and K concentrations of submandibular saliva were significantly higher than with carbachol or parasympathetic stimulation, and resembled those of alpha-adrenergic stimulation. The protein concentrations of physostigmine-evoked saliva from both glands were similar. The amylase activity of physostigmine-evoked parotid saliva was much higher than that of carbachol or parasympathetic stimulation. Physostigmine-evoked secretion was completely blocked by atropine, a cholinergic antagonist, and by reserpine, partially blocked by phentolamine, an alpha-adrenergic antagonist and not affected by surgical sympathectomy. Morphologically, physostigmine resulted in a moderate decrease in the number of acinar, but not ductal, secretory granules of both the parotid and submandibular glands, while the sublingual gland was unaffected. Numerous patches of parotid acini also developed vacuoles or vesicles. These results suggest that physostigmine-induced salivary secretion is mediated primarily by direct effects on cholinergic and alpha-adrenergic receptors.
Yu
J H
JH
Department of Physiology and Biophysics, Georgetown University Medical Center, Washington, DC 20007.
Redman
R S
RS
D000818:Animals; D003594:Cytoplasmic Granules / Q000187:drug effects; D008297:Male; D010306:Parotid Gland / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D010646:Phentolamine / Q000494:pharmacology; D010830:Physostigmine / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012110:Reserpine / Q000494:pharmacology; D012463:Saliva / Q000378:metabolism*; D012469:Salivary Glands / Q000187:drug effects*; D012636:Secretory Rate / Q000187:drug effects; D013363:Submandibular Gland / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D013562:Sympathectomy
D012110:Reserpine; D010830:Physostigmine; D011433:Propranolol; D010646:Phentolamine